Virtual 2020 BioHealth Capital Region Forum

Top 3 by 2023

SAVE THE DATE! October 19, 2020


20% of the top influencers worldwide in vaccine development


World-class tech + big data + biotech + White House Precision Medicine Initiative = new frontiers in patient-centered medicine


MD | DC | VA

Our Goal: To become a Top 3 BioHealth Hub by 2023.

We are the research engine for the nation and the world. A lifeblood of support for taking new medicines to market. A place where health policymakers and patient advocates seek a better way forward. A home to the established and the startup, pioneering big ideas for human health and hope.

Driving Innovation and Entrepreneurship

  • World–renowned research institutions and universities
  • Influential policymakers and advocacy groups pioneering new health strategies
  • World–leading infectious disease research and vaccine development
  • Fastest growing region for healthcare companies in the U.S.
  • Rated #1 in the nation for science and engineering talent
  • Mission control for the National Cancer Moonshot Initiative

Founding Partners

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

July 8, 2020

APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials VIENNA, AUSTRIA and GAITHERSBURG, MD, July 8, 2020 APEIRON Biologics…

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

July 8, 2020

Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military…

GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

July 7, 2020

• Collaboration combines innovative plant-based and adjuvant technologies to develop and produce a COVID-19 candidate vaccine. • Phase 1 clinical testing scheduled to begin mid-July • Collaboration to explore vaccine…

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate

July 6, 2020

Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at approximately $480 million…

Novavax Announces Updates to Leadership Team

July 2, 2020

GAITHERSBURG, Md., July 02, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales,…

Protaryx Medical Announces $8.3M in Funding for First-in-Class Technology for Left Atrial Access in Transcatheter Cardiac Procedures

June 30, 2020

$5.1M Series A Funding Led by Ajax Health Will Be Used to Develop First-in-Class Product Designed with Three-Dimensional, Independent Steerability to Deliver Reliable Access June 30, 2020 08:00 AM Eastern…